Belite Bio assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Belite Bio (BLTE) with an Overweight rating and $154 price target Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the readout notable because the one-year futility analysis already achieved statistical significance, the FDA granted breakthrough designation based on that interim success, and multiple regulators, including in China and the U.K., have agreed to accept filings using the interim data, the analyst tells investors in a research note.